Transition to tenecteplase is associated with shorter door-to-puncture times: a retrospective study from the Lone Star Stroke consortium TNK registry
Authors:
Open Access
- 4 May 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1804177
Abstract
Background: Intravenous thrombolytic (IVT) and mechanical thrombectomy (MT) therapies are the current standard of care for large vessel occlusion (LVO) stroke. Multiple studies emphasized the impact of time metrics on patient outcomes, particularly door-to-needle (DTN) and door-to-puncture (DTP) times. Tenecteplase (TNK) offers potential advantages over alteplase (ALT), including a simplified one-time bolus administration, which may reduce DTP time. Results suggest TNK is non-inferior to ALT in terms of clinical outcomes, but few large cohort studies have compared DTP time for patients receiving TNK vs. ALT prior to thrombectomy. This real-world study aimed to compare DTP times and discharge outcomes in patients treated with TNK vs. ALT before thrombectomy. Methods: Retrospective data were collected from three comprehensive stroke centers (CSCs) in Texas from October 2019 to November 2024 and included subjects that received both IVT and MT. Data were analyzed for DTP times and other time metrics. Results: Among 50 ALT and 89 TNK patients in our study cohort, the TNK group had significantly shorter DTP times of 80 min (62–96) compared to ALT times of 101.5 min (80–121), P < 0.001. No significant differences were found for door-to-imaging and imaging-to-needle times; however, needle-to-puncture times were significantly shorter with TNK 39 min (29–51) compared to ALT 55 min (43–77), P < 0.001. Both groups had similar favorable outcomes at discharge. Conclusions: Our Lone Star Stroke (LSS) TNK registry represents the real-world experience of academic CSCs in Texas. We demonstrated that transitioning to TNK is associated with shorter DTP times compared to ALT. These results are primarily due to shorter needle-to-puncture times and may be attributable to TNK's simplified single-bolus administration. Both TNK and ALT groups demonstrated high rates of favorable outcomes at discharge, but given its faster DTP time, TNK is likely a preferable option for LVO stroke patients requiring both IVT and MT.Keywords
This publication has 25 references indexed in Scilit:
- Intravenous Tenecteplase before Thrombectomy in StrokeNew England Journal of Medicine, 2025
- Infarct Growth in Patients with Emergent Large Vessel Occlusion Stroke Transferred for Endovascular ThrombectomyNeurology and Therapy, 2024
- Door to needle time trends after transition to tenecteplase: A Multicenter Texas stroke registryJournal of Stroke and Cerebrovascular Diseases, 2024
- Time to IVT Treatment and Functional Outcomes in Acute Ischemic Stroke—ReplyJAMA, 2024
- Ischemic stroke subtypes: risk factors, treatments, and 1-month prognosis – The Lille, France Stroke RegistryJournal of Stroke and Cerebrovascular Diseases, 2024
- Multicenter exploration of tenecteplase transition factors: A quantitative analysisJournal of Stroke and Cerebrovascular Diseases, 2024
- A qualitative study of barriers and facilitators to using tenecteplase to treat acute ischemic strokeJournal of Stroke and Cerebrovascular Diseases, 2023
- Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical PracticeJAMA, 2019
- Tenecteplase versus Alteplase before Thrombectomy for Ischemic StrokeNew England Journal of Medicine, 2018
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995